课题组前期研究发现蒙药苏格木勒-3汤(SD-3)对ISO诱导的大鼠心肌肥厚模型有很好的治疗作用。虽然也进行了一些作用机制初探，但是尚不完善，本课题拟采用RNA-Seq技术和iTRAQ 定量蛋白质组技术对于蒙药SD-3治疗心肌肥厚机制进行系统研究。①采用异丙肾上腺素诱导大鼠心肌肥厚模型，采用生理、生化、心功等指标检测造模情况及给药后对心肌肥厚治疗情况进行评价，并获取组织样本；②利用RNA-Seq 基因测序技术和定量蛋白质组技术两种层次的整合分析技术解析蒙药SD-3对于ISO诱导大鼠心肌肥厚治疗机制和药物作用靶点；③对于蒙药SD-3治疗ISO诱导大鼠心肌肥厚模型等实验，利用上述系统生物学技术手段分析确定分子机制，为后续临床用药提供指导。本项课题将紧密结合蒙医临床用药，用现代药理学、生物化学、系统生物学和生物信息学等研究方法，阐明蒙药治疗心肌肥厚的科学内涵，试图开创蒙药现代研究的新领域、新途径。

The early study of our panel found that Mongolian medicine SD-3 had a good therapeutic effect on ISO-induced rat myocardial hypertrophy. Although there are some preliminary studies on the mechanism of action, it is not perfect. In this subject, we intend to systematically study the mechanism of Mongolian medicine SD-3 in the treatment of myocardial hypertrophy by RNA-Seq and iTRAQ quantitative proteome. ①The rat model of myocardial hypertrophy was induced by isoproterenol, the model was measured and the treatment of myocardial hypertrophy was evaluated by physiological, biochemical and cardiac function indexes, and tissue samples were obtained. ②The therapeutic mechanism and drug targets of Mongolian medicine SD-3 for ISO-induced myocardial hypertrophy in rats were analyzed by using RNA-Seq gene sequencing and quantitative proteomics. ③Confirm the molecular mechanism for the experiments of Mongolian medicine SD-3 in treating ISO-induced rat myocardial hypertrophy by using the above systematic biological techniques, which provide guidance for subsequent clinical medication. This project will combine tightly with Mongolian medicine to clarify the scientific connotation of Mongolian medicine in treating myocardial hypertrophymodern pharmacology by using Modern pharmacology, biochemistry, systematic biology and bioinformatics, and try to create new fields and new ways for modern Mongolian Medicine research.